Mercury poisoning

disease
On this page

Also known as hydrargyriamercurialismMercury intoxicationMercury toxicity

Summary

Mercury poisoning (MONDO:0018020) is a disease and 3 clinical trials. Top therapeutic interventions include emeramide and magnesium stearate. A subtype of poisoning — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Prevalence: 1-9 / 100 000 (Europe) [Orphanet-validated]
  • Phenotypes (HPO): 21
  • Clinical trials: 3

Clinical features

Epidemiology

Prevalence records

1 prevalence record(s), Orphanet:

TypeClassValueGeographyValidation
Point prevalence1-9 / 100 000EuropeValidated

Signs & symptoms

Clinical features (HPO)

21 HPO clinical features (Orphanet curated; top 21 by frequency):

HPO IDTermFrequency
HP:0000822HypertensionFrequent (30-79%)
HP:0001250SeizureFrequent (30-79%)
HP:0001289ConfusionFrequent (30-79%)
HP:0001332DystoniaFrequent (30-79%)
HP:0001337TremorFrequent (30-79%)
HP:0001649TachycardiaFrequent (30-79%)
HP:0001919Acute kidney injuryFrequent (30-79%)
HP:0002018NauseaFrequent (30-79%)
HP:0002039AnorexiaFrequent (30-79%)
HP:0002094DyspneaFrequent (30-79%)
HP:0002098Respiratory distressFrequent (30-79%)
HP:0002500Abnormal cerebral white matter morphologyFrequent (30-79%)
HP:0002572Episodic vomitingFrequent (30-79%)
HP:0002574Episodic abdominal painFrequent (30-79%)
HP:0002615HypotensionFrequent (30-79%)
HP:0002878Respiratory failureFrequent (30-79%)
HP:0002900HypokalemiaFrequent (30-79%)
HP:0003324Generalized muscle weaknessFrequent (30-79%)
HP:0006515Interstitial pneumonitisFrequent (30-79%)
HP:0007185Loss of consciousnessFrequent (30-79%)
HP:0100785InsomniaFrequent (30-79%)

Identifiers

Disease identifiers

FieldValue
Canonical namemercury poisoning
Mondo IDMONDO:0018020
EFOEFO:1001810
MeSHD008630
Orphanet330021
SNOMED CT85180002
GARD0007021
Is cancer (heuristic)no

Also known as: hydrargyria · mercurialism · Mercury intoxication · Mercury toxicity

Disease family

This is a subtype of poisoning. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › poisoningmercury poisoning

Related subtypes (58): toxic oil syndrome, infantile mercury poisoning, ketamine-induced biliary dilatation, manganese poisoning, cyanide-induced parkinsonism, colchicine poisoning, methanol poisoning, ethylene glycol poisoning, paraquat poisoning, lead poisoning, acute opioid poisoning, acute tricyclic antidepressant poisoning, acute poisoning by drugs with membrane-stabilizing effect, snakebite envenomation, paracetamol poisoning, cyanide poisoning, scorpion envenomation, argyria, acute ackee fruit intoxication, cocaine intoxication, systemic monochloroacetate poisoning, water intoxication, cassavism, formaldehyde poisoning, heavy metal poisoning, abacavir toxicity, allopurinol toxicity, codeine toxicity, efavirenz toxicity, flucloxacilline toxicity, isoniazid toxicity, raltegravir toxicity, voriconazole toxicity, curariform drugs toxicity, statin toxicity, phenytoin or carbamazepine toxicity, letrozole toxicity, ricin poisoning, ivermectin toxicity, belinostat toxicity or dose selection, toxicity to dolutegravir, mycotoxicosis, ciguatera fish poisoning, lathyrism, cadmium poisoning, phenytoin toxicity, nerve agent poisoning, local anesthetic poisoning, fire ant poisoning, aflatoxicosis, black widow spider envenomation, platinum-induced ototoxicity, carbon monoxide poisoning, organophosphate poisoning, sulfur mustard poisoning, cardiac glycoside intoxication, monochloroacetic acid poisoning, chemotherapy-induced toxicity

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 3.

Phase distribution (across all retrieved trials)

PhaseTrials
PHASE2/PHASE31
PHASE21
Not specified1

Top trials by phase / activity

NCTPhaseStatusTitle
NCT04183595PHASE2/PHASE3UNKNOWNNBMI Treatment in Patients With Mercury Toxicity
NCT02486289PHASE2COMPLETEDPilot Proof of Concept Study of NBMI Treatment of Mercury Intoxication
NCT00013858Not specifiedCOMPLETEDEnvironmental Contaminants and Infant Development

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
EMERAMIDE21
MAGNESIUM STEARATE11

No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.